anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

234,061-234,120 of 319,975

filter-aware
01
Slide 1
AstraZeneca | Results Presentation Deck | 157 slidesAstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem1 hit
02
The slide uses a grid layout to present four key performance indicators related to the drug development pipeline.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem1 hit
03
The slide uses a matrix-like layout to categorize events by time period and event type (regulatory vs. data readout).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem1 hit
04
The slide uses a matrix-like layout to organize drug assets by therapeutic area and development stage (approved vs. pipeline).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem1 hit
05
The slide uses a four-column layout to track drug development progress.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem1 hit
06
The slide tracks changes in drug development pipeline status since the Q2 2024 update.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
07
The slide uses a grid-based layout to list specific drug assets and their indications within each phase column.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
08
The slide uses a grid-based layout to represent the drug development pipeline.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
09
The slide uses a grid-based layout to organize drug candidates by development stage. It includes a legend for '# Partnered and/or in collaboration' and a yellow dot for 'Precision medicine approach being explored'.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
10
The slide uses a timeline-like structure to categorize drug development projects by clinical phase.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The slide uses a Kanban-style board to visualize drug development stages.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide uses a color-coded system to distinguish between Oncology, Biopharmaceuticals, and Rare Disease designations.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
AstraZeneca | Results Presentation Deck | 157 slidesAstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide uses a color-coded sidebar to indicate the development stage of the drug across different therapeutic areas.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide provides a detailed overview of seven specific clinical trials (AEGEAN, ADJUVANT BR.31, PACIFIC-4, PACIFIC-5, PACIFIC-8, ADRIATIC, PACIFIC-9).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
The slide uses a standard clinical trial registry format.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
The slide is part of an appendix, providing detailed clinical trial data for Imfinzi.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The slide uses a standard clinical trial registry format.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide is part of an appendix section detailing clinical trial status for specific drug assets.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
The slide is part of an appendix, likely from a pharmaceutical investor presentation.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
The slide uses a vertical tab structure on the right to categorize the therapeutic area (Oncology).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
22
The slide provides a structured overview of three specific clinical trials: DESTINY-Gastric04, 06, and 03.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
23
The slide is part of an appendix, indicated by the footer and the 'Other' tab in the right-hand navigation.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
24
The slide uses a standard clinical trial pipeline table format.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
25
The slide uses a standard clinical trial registry format for reporting pipeline progress.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
26
The slide uses a standard clinical trial registry format for portfolio tracking.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
27
The slide is part of an appendix, specifically detailing clinical trial status for a specific drug.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
28
The slide provides a structured overview of four specific clinical trials (LAURA, ADAURA2, NeoADAURA, FLAURA2).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
29
The slide provides a structured overview of five specific clinical trials (SAFFRON, SANOVO, SACHI, SAVANNAH, ORCHARD) including patient counts and trial arms.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
30
The slide uses a color-coded sidebar on the right to categorize the drug's development stage (Oncology).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
31
The slide provides a structured overview of five specific clinical trials (TROPION-Breast01 through 05).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
32
The slide is part of an appendix, indicated by the footer and the 'Appendix' label.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
33
The slide is part of an appendix, specifically detailing late-stage development assets in Oncology.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
34
The slide is part of an appendix, indicated by the page number 34 and the 'Appendix: Glossary' link at the bottom.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
35
The slide is part of an appendix section, indicated by the page number and glossary link.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
36
The slide is part of an appendix, detailing specific trial designs, patient counts, and status for TROPION-PanTumor trials.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
37
The slide uses a vertical navigation bar on the right to indicate the drug's development stage (Late-stage development) and therapeutic area (Oncology).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
38
Includes trial identifiers (NCT numbers) and status timelines.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
39
The slide is an appendix page detailing clinical trial pipeline data for a specific drug.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
40
The table lists five distinct clinical trials (SERENA-2, SERENA-3, NCT04541433, SERENA-1, NCT04818632).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
41
The slide is part of an appendix section detailing clinical trial pipelines.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
42
The slide is part of an appendix, specifically detailing late-stage development assets.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
43
The slide is part of an appendix, providing detailed clinical trial data for a specific asset.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
44
The slide provides a structured overview of four specific clinical trials (EvoPAR-Prostate01, EvoPAR-Breast01, PETRA, PETRANHA).AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
45
The slide is part of an appendix, providing specific clinical trial data for a drug candidate.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
46
The slide is an appendix page detailing the clinical development pipeline for a specific drug candidate.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
47
Slide 47 of a presentation deck.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
48
AstraZeneca | Results Presentation Deck | 157 slidesAstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
49
Slide 49 of a presentation deck.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
50
Part of a pipeline appendix deck.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
51
Slide 51 of a presentation deck.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
52
Part of a larger portfolio deck, indicated by the vertical navigation bar on the right.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
53
The slide is part of an appendix, providing detailed clinical trial data for a specific drug candidate.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
54
Slide 54 of a larger deck, part of the appendix.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
55
Slide 55 of a presentation deck.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
56
Part of a clinical pipeline appendix.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
57
The slide provides a summary of two clinical trials (PRIMROSE and PRIMAVERA) including population, patient counts, design, endpoints, and status.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
58
Part of a corporate presentation appendix, specifically under the Oncology pipeline section.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
59
The slide uses a standard clinical trial table format common in pharmaceutical investor presentations.AstraZeneca | Results Presentation Deck | 157 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution1 hit
38
Data presented as stacked bar charts with corresponding data tables below each chart.AstraZeneca | Results Presentation Deck | 38 slides · AstraZeneca
Conference presentation Investor relations 1 hit